CTLA4 and neoplasm: For example, one could envision combination therapies that physically alter the tumor microenviroment by enzymatic degradation via recombinant human hyaluronidase (PEGPH20)30,31, or other alternative chemotherapy agents, and/or alternative checkpoint inhibitors that may promote a synergistic effect in activating T-cells (PD-1 and CTLA-4).